Check out our COVID-19 dedicated page for tenders related to medical equipment needs.
Belgium-Brussels: Production, Priority-purchasing Options and Supply of Covid-19 Vaccines, Including Adapted Vaccines to SARS-CoV-2 Variants and Paediatric Formulations of such Vaccines for EU Member States
Contract award notice
Results of the procurement procedure
Section I: Contracting authority
Section II: Object
Production, priority-purchasing options and supply of COVID-19 Vaccines, including adapted vaccines to SARS-CoV2 variants and paediatric formulations of such vaccines for EU Member States
The subject of this tender is the production, priority-purchasing options and supply of mRNA based COVID-19 Vaccines, developed and produced by BioNTech-Pfizer-, for the participating Member States, and adapted vaccines for SARS-CoV2 variants and pediatric formulations of such vaccines.
Please see Point II.1.4 of the present notice.
The maximum value of the contract, provided in point II.1.7, will not be mentioned in the contract award notice due to article 163.3 of the Financial Regulation. The value stated in sections II.1.7 and V.2.4 should therefore be disregarded.
Section IV: Procedure
It currently appears that BioNTech / Pfizer is the only candidate that can reliably deliver a very large number of doses produced within the EU of an efficient, safe and adaptable vaccine conferring immunity to SARS-CoV2.
In addition, the Commission needs to secure the purchase of the vaccine in advance in order to receive a timely delivery, essential for the organisation of the large-scale vaccination campaign.
Section V: Award of contract
Section VI: Complementary information